TY - JOUR
T1 - Brentuximab as a treatment for CD30+ mycosis fungoides and Sézary syndrome
AU - Mehra, Tarun
AU - Ikenberg, Kristian
AU - Moos, Rudolf Maria
AU - Benz, Rudolf
AU - Nair, Gayathri
AU - Schanz, Urs
AU - Haralambieva, Eugenia
AU - Hoetzenecker, Wolfram
AU - Dummer, Reinhard
AU - French, Lars Einar
AU - Guenova, Emmanuella
AU - Cozzio, Antonio
PY - 2015/1
Y1 - 2015/1
N2 - IMPORTANCE: The prognosis of advanced cutaneous T-cell lymphoma (CTCL), including Sézary syndrome and mycosis fungoides (MF), is poor. So far, no curative option apart from allogeneic stem cell transplantation is available. Large cell transformation often hallmarks cases with a more aggressive clinical course, and large tumor cells may express CD30. Recently, brentuximab vedotin, a conjugate of an anti-CD30 antibody and monomethylauristatin E, which inhibits the polymerization of microtubuli, has produced promising results in phase 2 trials in CD30+ Hodgkin lymphoma and anaplastic large cell lymphoma.OBSERVATIONS: We describe 4 patients with advanced CTCL, 3 with MF and 1 with Sézary syndrome, who were treated with brentuximab. All patients had received multiple previous systemic therapies. In 2 cases of MF, a remission enabling subsequent allogeneic stem cell transplantation was achieved.CONCLUSIONS AND RELEVANCE: Brentuximab is a well-tolerated, promising new treatment option for advanced CTCL that can be integrated in an allogeneic stem cell transplantation plan by selectively depleting malignant CD30+ cutaneous lymphoma cells.
AB - IMPORTANCE: The prognosis of advanced cutaneous T-cell lymphoma (CTCL), including Sézary syndrome and mycosis fungoides (MF), is poor. So far, no curative option apart from allogeneic stem cell transplantation is available. Large cell transformation often hallmarks cases with a more aggressive clinical course, and large tumor cells may express CD30. Recently, brentuximab vedotin, a conjugate of an anti-CD30 antibody and monomethylauristatin E, which inhibits the polymerization of microtubuli, has produced promising results in phase 2 trials in CD30+ Hodgkin lymphoma and anaplastic large cell lymphoma.OBSERVATIONS: We describe 4 patients with advanced CTCL, 3 with MF and 1 with Sézary syndrome, who were treated with brentuximab. All patients had received multiple previous systemic therapies. In 2 cases of MF, a remission enabling subsequent allogeneic stem cell transplantation was achieved.CONCLUSIONS AND RELEVANCE: Brentuximab is a well-tolerated, promising new treatment option for advanced CTCL that can be integrated in an allogeneic stem cell transplantation plan by selectively depleting malignant CD30+ cutaneous lymphoma cells.
KW - Adult
KW - Aged
KW - Brentuximab Vedotin
KW - Combined Modality Therapy
KW - Female
KW - Humans
KW - Immunoconjugates/adverse effects
KW - Ki-1 Antigen/immunology
KW - Male
KW - Middle Aged
KW - Mycosis Fungoides/drug therapy
KW - Prognosis
KW - Sezary Syndrome/drug therapy
KW - Skin Neoplasms/drug therapy
KW - Stem Cell Transplantation/methods
KW - Transplantation, Homologous/methods
UR - https://www.scopus.com/pages/publications/84921342421
U2 - 10.1001/jamadermatol.2014.1629
DO - 10.1001/jamadermatol.2014.1629
M3 - Article
C2 - 25317818
SN - 2168-6068
VL - 151
SP - 73
EP - 77
JO - JAMA dermatology
JF - JAMA dermatology
IS - 1
ER -
